ChromaDex will provide Wageningen University with quantities of its proprietary NIAGEN nicotinamide riboside (NR) ingredient for research use. ChromaDex’s NIAGEN is the first and only commercially available form
Under this collaborative initiative, FORMA and Dr Ovaa will advance the research, discovery and clinical application of highly-selective, irreversible therapeutics. This represents a distinct and additional agreement between
This is the Company’s second IND to be allowed in the past 10 months that uses the Orascovery technology platform for oral delivery of anti-cancer drugs. In July
Auven intends to conduct a Phase II (proof-of-concept) clinical trial to evaluate KIACTA’s effectiveness and safety to treat certain medical manifestations of sarcoidosis. Kiacta is aimed at addressing
The DSMB did not identify any safety concerns for the patients enrolled in the trial. Based on the DSMB recommendation and while further review of the data is
The company is currently developing a response to address the items outlined in the letter. Acorda president and CEO Dr Ron Cohen noted that there is an urgent
ORALAIR is an allergen extract indicated as immunotherapy for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis confirmed by positive skin test or in vitro
CRF trustee and president Nancy Stack noted that the foundation is on the brink of new possibilities and treatments. Stack spoke of CRF-funded stem cell and gene therapy
This patent, along with related patents issued in June 2013 (US Patent no. 8,461,157) and February 2013 (US Patent No. 8,367,663), covers a broad range of proprietary chemical
Alcobra president and CEO Dr Yaron Daniely noted that the company is pleased that the USPTO granted us this second important patent. "As we expand clinical trials and
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.